Background & Summary
====================

An estimated 15,780 children were diagnosed with cancer in 2014 In the United States, and per year globally, this number is nearly 250,000 ([@b1]). Although the 5-year survival rate of pediatric cancers is \~80%, many of the most commonly diagnosed childhood cancers: brain tumors, Wilms tumor, rhabdomyosarcoma, and high-risk neuroblastoma, have devastatingly low rates of survival^[@b1]^, demonstrating the continued need for research progress in these areas. Here, we focus on neuroblastoma, the most common extracranial solid tumor in children. This disease has an estimated incidence of 1 in 8,000 to 10,000 births^[@b2]^ and a 5-year survival rate of \>95% for children in the low and intermediate risk groups. However, children with high-risk disease have only a 40% likelihood of survival^[@b2]^. Culturing of neuroblastoma cell lines dates back to the 1940s ([@b3]), during which the sole purpose of culturing was for diagnosis. However, producing cell lines from neuroblastoma tumors quickly became routine (see review^[@b4]^) and today, they are commonly-used, highly-characterized models used in laboratories across the world. Neuroblastoma cell lines nicely model a tumor's histopathology, gene expression, aneuploidy, and drug sensitivity, thus they are routinely used to investigate oncogenes or signaling pathways pharmacologically (drug screens, drug sensitivity/resistance) and/or genetically (siRNA, shRNA, CRISPR).

The genomics of neuroblastoma cell lines have been previously characterized using SNP^[@b5]^, methylation^[@b5],[@b6]^, and/or mRNA expression microarrays^[@b7]^, however, there has not been an effort to profile a large panel of these cell lines with high-throughput sequencing techniques. The motivation behind this study was to comprehensively profile the mRNA and non-coding RNA transcriptome of commonly-used neuroblastoma cell line models with a major goal of using this information as a complement to the epigenomic data currently available and the many data in the process of being generated. Integration of RNA expression patterns with histone and/or transcription factor chromatin immunoprecipitation (ChIP) sequencing is necessary for inferring transcriptional regulatory events. Neuroblastomas can be classified into various groups based on genetic lesions, for example: MYCN copy number amplification, harboring an activating *ALK* mutation, harboring a chromosomal loss (e.g.,: 1p, 3p, 11q) or gain (17q), *TERT* rearrangements (for review of neuroblastoma genomics, see [@b10]). Utilizing a panel of cell lines which harbor a mixture of these characteristics enables differential expression analyses on the basis of a genetic lesion, mutation of interest, or expression of a gene of interest.

These data have reuse value to inform selection of cell lines for experimental investigation of putative neuroblastoma oncogenes and/or tumor suppressors. For example, choice of knock-down or over-expression studies require *a priori* knowledge of basal expression of the gene of interest for rational experimental design. These data allow the experimenter to quickly determine which cell lines are high, mid, or low expressers of a gene of interest without requiring tedious quantitative, real-time PCR analysis or western blotting of multiple cell lines prior to initiating a gene over-expression or knockdown experiment.

Here, we describe transcriptome-wide profiling of 39 neuroblastoma cell lines, the hTERT-immortalized retinal pigmented epithelial cell line, RPE-1, and pooled human fetal brain tissue. Careful and stringent technical design at each experimental stage has allowed generation of a high-quality RNA-Seq dataset which has tremendous reuse value for the neuroblastoma community. An overview of the study design is depicted in [Fig. 1](#f1){ref-type="fig"}. Briefly, cell lines were thawed, grown, and collected at 60--80% confluency over a two-month period. Once all cell lines were pelleted, RNA extractions were performed, quality of RNA inspected, and RNA sequencing was performed. Raw FASTQ files were generated and are publicly-available for reuse (see Data Citation 1). Additionally, we provide a processed file of gene-level mRNA abundances for each sample. We anticipate this data being a valuable tool for the neuroblastoma research community as we continue investigation into oncogenomic mechanisms of this disease.

Methods
=======

Cell lines and culturing
------------------------

Cell line stocks were obtained from the Children's Oncology Group (COG) Cell Culture and Xenograft Repository at Texas Tech University Health Sciences Center ([www.COGcell.org](http://www.COGcell.org)), the American Type Culture Collection (Manassas, VA), or the Children's Hospital of Philadelphia (CHOP) cell line bank. Several of the COG-derived cell lines were established direct-to-culture in parallel with a patient-derived xenograft model^[@b11]^ that are being characterized separately (see [Table 1](#t1){ref-type="table"} (available online only)). All cell culturing for this experiment was performed at CHOP. Each cell line was thawed for 2--3 min in a 37 °C water bath, added to a 15 ml tube containing its respective growth medium, and pelleted by centrifugation at 300×g for 3 min. The supernatant was discarded to remove the DMSO-containing freezing medium. Cells were re-suspended in 1 ml of growth medium and transferred into a T75 flask containing an additional 10 ml of growth medium. Once cells were \~70--80% confluent, they were transferred to a 150 mm dish. At \~70--80% confluency, cells were split into two 150 mm dishes and at \~70--80% confluency, each dish of cells was pelleted, washed 3x with 1X PBS, and frozen at −80C until nucleic acids were extracted. See [Table 1](#t1){ref-type="table"} (available online only) for a complete listing of cell lines, whether a matched patient-derived xenograft (PDX) exists, and their growth medium. Cell lines appended with 'nb' were grown in serum-free neurobasal medium. The following were purchased from Thermo Fisher Scientific (Waltham, MA): Iscove's IMDM (Cat\# 12440053), RPMI 1640 with 25 mM HEPES (Cat\# 22400089), Neurobasal-A Medium (Cat\# 10888022), L-glutamine (Cat\# 25030081), antibiotic/antimycotic (Cat\# 15240062), 50X B-27 serum-free supplement (Cat\# 18504044), 100X N-2 supplement (Cat\# 17502048). The following growth factors were purchased from VWR (Radnor, PA): rhFGF (fibroblast growth factor, Cat\# PAG5071) and rhEGF (epidermal growth factor, Cat\# PAG5021). Insulin/Transferrin/Selenium (ITS) premix culture supplement was purchased from Corning Life Sciences (Tewksbury, MA, Cat\# 354351). Hyclone Fetal bovine serum was purchased from Fisher Scientific (Cat\# SH30071.03) and the lot remained consistent across the different medium formulations throughout the duration of the experiment. Of note, SK-N-BE(2)-C is a subclone derived from the parental SK-N-BE(2) cell line^[@b12]^ and SH-SY5Y was derived from the SH-SY subclone of the parental SK-N-SH cell line^[@b13]^.

Throughout the duration of the study, randomization was implemented to ensure unbiased data production. Cell lines were thawed in random order, nucleic acid extractions were performed randomly, and library preps and sequencing were performed randomly. Phenotypic characteristics of each cell line were also assessed as quality control during the cell growth stage. No unusual morphologies or growth rates were noted.

DNA extraction and STR profiling
--------------------------------

From separate cell pellets, DNA was extracted using the DNeasy Blood & Tissue Kit (Cat\# 69504, Qiagen, Valencia, CA). DNA was quantitated using the Nanodrop 1000 (Thermo Fisher Scientific) and Short Tandem Repeat (STR) profiling employed either the AmpFLSTR Identifiler PCR Amplification kit (Applied Biosystems, Foster City, CA) by the Children's Hospital of Philadelphia Nucleic Acids and Protein Core or the PowerPlex Fusion kit (Promega, Madison, WI) by Guardian Forensic Sciences (Abington, PA). All cell line STRs matched publicly-available references listed at <http://strdb.cogcell.org/>.

RNA extraction
--------------

Control human fetal brain total RNA (Cat\# 636526, Lot\#1605061A) was purchased from Clontech Laboratories (Mountain View, CA). This RNA was a pool of normal brain tissue from 21 spontaneously aborted male/female Caucasian fetuses of ages 26--40 weeks and was isolated using a modified guanidinium thiocyanate method^[@b14]^. For all cell lines, RNA was extracted using the miRNeasy Mini kit (Cat\# 217004) from Qiagen (Valencia, CA) according to the manufacturer's protocol. RNA purity was assessed using the Nanodrop 2000 (Thermo Fisher Scientific) and quantitated with the Qubit 2.0 Fluorometer (Thermo Fisher Scientific). Quality and RNA integrity numbers (RINs) were assessed using the TapeStation 2200 (Agilent Technologies, Santa Clara, CA). Each cell line RNA sample had a RIN≥8.7 and the RIN for the fetal brain RNA was 7.6, thus all RNA was of high quality.

Library preparation and RNA sequencing
--------------------------------------

Libraries were prepared using 1 ug RNA according to the TruSeq Stranded Total RNA Sample Preparation guide (Part\# 15031048 Rev. E, October 2013, Illumina, San Diego, CA). Ribosomal RNA removal was performed using the Gold rRNA Removal Mix per Illumina\'s recommendations. Quality of each library assessed with the Agilent TapeStation 2,200. Six to eight libraries were pooled (*N*=6--8) and sequenced using v2 chemistry, 2×100 bp, on one high-output flow-cell of an Illumina NextSeq 500 to achieve at least 50 million paired reads per sample. Upon run completion, libraries were demultiplexed, Illumina adapters trimmed, and FASTQ files were generated using the Illumina NextSeq Control Software version 2.02.

Sequencing quality control
--------------------------

First, sample reads were concatenated for each paired read group. Next, FASTQC V0.11.4 (Babraham Institute, available for download at <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>) was run on all samples and inspected for sequencing quality. Next, Picard tools version 1.140 (Broad Institute, Cambridge, MA, available for download at <https://github.com/broadinstitute/picard/releases/tag/1.140>) was used to calculate insert sizes for GEO according to the following parameters:

`$ java -jar picard.jar CollectInsertSizeMetrics INPUT=Aligned.sortedByCoord.out.bam OUTPUT=filename`

Alignment and generation of counts
----------------------------------

The Spliced Transcripts Alignment to Reference (STAR) version 2.4.2a aligner (available for download at <https://github.com/alexdobin/STAR/releases/tag/STAR_2.4.2a>)^[@b15]^ was used to index the full hg19 genome fasta file from UCSC using the following parameters:

`$ STAR --runMode genomeGenerate --runThreadN 16 --genomeDir idx_dir --genomeFastaFiles ucsc.hg19.fa --sjdbGTFfile refSeq_hg19_2016-03-03.gtf --sjdbOverhang 100`

The GTF file was downloaded using the **genePredToGtf** command from the kent utility (available for download at <http://hgdownload.cse.ucsc.edu/admin/exe/linux.x86_64/>):

`$ genePredToGtf hg19 knownGene knownGene.gtf`

Next, sequences were aligned and counts per gene were generated using the following parameters in two-pass mode:

`$ STAR --runMode alignReads --runThreadN 16 --twopassMode Basic --twopass1readsN -1 --chimSegmentMin 15 --chimOutType WithinBAM --genomeDir dir --genomeFastaFiles ucsc.hg19.fa --readFilesIn R1.fastq.gz R2.fastq.gz --readFilesCommand zcat --outSAMtype BAM SortedByCoordinate --outFileNamePrefix $cellline. --quantMode TranscriptomeSAM GeneCounts --sjdbGTFfile refSeq_hg19_2016-03-03.gtf --sjdbOverhang 100`

Alignment resulted in an average of 66 million uniquely-mapped reads per sample. STAR two-pass mode alignment was chosen as it has been shown to have 99% alignment accuracy and has nearly 20x faster processing speed compared with TopHat2 and similar processing speed as HISAT two-pass mode^[@b16]^.

Generation of FPKM
------------------

A custom R script was used to generate gene fragments per kilobase of exons per million reads (FPKM) from the count data produced from STAR. The Genomic Features Package version 1.22.13 (available for download at <https://bioconductor.org/packages/release/bioc/html/GenomicFeatures.html>) was used with R Version 3.2.2 (Fire Safety) to make the transcriptome database and figures were produced using ggplot2 version 2.1.0 (<http://ggplot2.org/>).

Differential expression analyses
--------------------------------

Differential expression of genes based on *MYCN* amplification status was performed separately for cell lines and primary neuroblastoma tumor samples using the R package, DESeq2 (version 1.10.1)^[@b17]^. FASTQ files and *MYCN* status for patient tumors were obtained with consent through the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Consortium (see Data Citation 2, <https://ocg.cancer.gov/programs/target/data-matrix>). Next, the differentially-expressed genes' log~2~-transformed mean expression and the log~2~ fold-change were correlated between the cell lines and patient samples.

Code availability
-----------------

R scripts for generation of FPKM and differential expression analyses are available for download at: <https://github.com/marislab/NBL-cell-line-RNA-seq>.

Data Records
============

All raw RNA-sequencing data (paired FASTQ files) as well as the processed FPKM matrix from this study have been deposited into the Gene Expression Omnibus (GEO) under Accession Number GSE89413 (see Data Citation 1). For associated specimen metadata, see [Table 1](#t1){ref-type="table"} (available online only) and for associated assay metadata, see [Table 2](#t2){ref-type="table"} (available online only). Raw single nucleotide polymorphism (SNP) array IDAT files and processed Genome Studio files for 27 of the cell lines have been deposited into GEO under Accession Number GSE89968 (see Data Citation 3). Together, these data make up the GEO Super Series GSE89969.

Technical Validation
====================

As a technical validation of our RNA-Seq data, we generated FPKM for all genes (See Methods and Data Citation 1) and compared *MYCN* FPKM with each cell line's known copy number amplification status across cell lines ([Fig. 2](#f2){ref-type="fig"} and [Table 3](#t3){ref-type="table"} (available online only)) . Of note, the tumor from which the NLF cell line was derived was *MYCN* copy number amplified by the fluorescence *in situ* hybridization, however, it is not amplified at the protein level^[@b18]^ and therefore, as expected, has the lowest *MYCN* FPKM of all cell lines designated as *MYCN* amplified. All cell lines were concordant with known *MYCN* amplification status.

Next, for both cell lines and neuroblastoma patient data, we performed differential expression analyses based on *MYCN* genomic amplification status using the R package, DESeq2 ([@b17]). We correlated the DESeq2 base mean of the common differentially-expressed genes (*N*=2,395) between cell lines and primary patient tumors, which were significantly correlated ([Fig. 3a](#f3){ref-type="fig"}, Pearson's R=0.824, t=71.131, df=2,393, 95% CI=0.811--0.836, *P*\<2.2 e-16). The fold changes of these genes were also significantly correlated between the cell lines and patient samples ([Fig. 3b](#f3){ref-type="fig"}, Pearson's R=0.73, t=52.231, df=2,393, 95% CI=0.711--0.748, *P*\<2.2 e-16), not only supporting the technical validity of our dataset, but also emphasizing the utility of these cell lines as a surrogate model for neuroblastoma.

Finally, we correlated non-differentially expressed genes (DESeq2 p-adjusted \> 0.20) between the cell lines and patient tumors (*N*=6,523). As expected, base mean expression of the genes correlated significantly ([Fig. 3c](#f3){ref-type="fig"}, Pearson's R=0.829, t=119.74, df=6,521, 95% CI=0.821--0.837, *P*\<2.2 e-16). While correlating fold-change yields a significant *P*-value because of the large number of genes analyzed, it is clear that the relationship is weak, as the correlation is close to zero ([Fig. 3d](#f3){ref-type="fig"}, Pearson's R=0.052, t=4.1,766, df=6,521, 95% CI=0.027--0.076, *P*\<3 e-5). This is expected, as all fold-changes of non-DE genes are close to zero.

Usage Notes
===========

All raw FASTQ files and the associated FPKM matrix file can be downloaded from the Gene Expression Omnibus (GEO) under Accession Number GSE89413. STAR-Fusion (<https://github.com/STAR-Fusion/STAR-Fusion>) enables detection of fusion transcripts. Alternative gene expression analyses can be performed using RSEM^[@b19]^ and/or transcript level analyses can be performed using kallisto^[@b20]^. Use of kallisto will also allow quantification of non-coding RNA abundances. Differential expression analyses may be performed using the common R packages, limma^[@b21]^ or DESeq2 ([@b17]). Differentially expressed gene lists can be explored for enrichment in signaling pathways using Ingenuity Pathway Analysis (Qiagen, <http://www.ingenuity.com/products/ipa>) and/or gene ontologies using ToppGene^[@b22]^ or the Gene Ontology Consortium tool^[@b23]^. Finally, these expression data can be integrated with epigenomics datasets (e.g.: ChIP-Seq, DNase-Seq/ATAC-Seq, Histone ChIP-Seq) to infer transcriptional regulation or repression.
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![Experimental and data analysis workflow.\
Cell lines were thawed and cultured to \~60--80% confluence before passaging and finally, pelleting. RNA was extracted, sequencing performed, and data analysis performed as described.](sdata201733-f1){#f1}

![Validation of *MYCN* genomic amplification status in neuroblastoma cell lines.\
Plotted are rank-ordered *MYCN* FPKM values for the human fetal brain sample and each cell line, colored by known *MYCN* copy number status. These data validate known *MYCN* amplification status for each cell line.](sdata201733-f2){#f2}

![Concordance of differentially-expressed genes between neuroblastoma cell lines and primary tumors.\
(**a**) Across the neuroblastoma cell lines, 3,940 genes were differentially-expressed (DE) based on *MYCN* amplification status and of those, 2,395 were differentially-expressed based on *MYCN* amplification status in primary tumors and were significantly correlated (Pearson's R=0.824, *P*\<2.2 e-16). (**b**) The fold changes of these DE genes were significantly correlated between the cell line dataset and the patient tumor dataset (Pearson's R=0.73, *P*\<2.2 e-16). (**c**) A significant correlation between the common 6,523 genes that were not DE in cell lines and tumors was observed (Pearson's R=0.829, *P*\<2.2 e-16). (**d**) As expected, correlation of the non-DE genes' fold changes was close to zero (Pearson's R=0.052, *P*\<3 e-5).](sdata201733-f3){#f3}

###### Associated metadata for the cell lines used in this study

  **Source Name**           **Characteristics \[organism\]**   **Characteristics \[organism part\]**            **Characteristics \[Matched PDX\]**                 **Method**         **Sample Name**                                **Factor Value \[Growth Media\]**                                **Factor Value \[Detachment Method\]**
  ------------------------ ---------------------------------- --------------------------------------- ------------------------------------------------------- ---------------------- ------------------- -------------------------------------------------------------------------------------------- ----------------------------------------
  CHP-134 cell line                   Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction        CHP-134                    RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  CHP-212 cell line                   Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction        CHP-212                    RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  COG-N-415 cell line                 Homo sapiens                         Neuroblastoma                                    COG-N-415x                         Total RNA extraction       COG-N-415       IMDM, 20% FBS, 1% Penicillin/Streptomycin, 2 mM L-glutamine, 1:1,000 ITS Premix Supplement                    n/a
  COG-N-440 cell line                 Homo sapiens                         Neuroblastoma                                    COG-N-440x                         Total RNA extraction       COG-N-440       IMDM, 20% FBS, 1% Penicillin/Streptomycin, 2 mM L-glutamine, 1:1,000 ITS Premix Supplement               0.02% Versene
  COG-N-453 cell line                 Homo sapiens                         Neuroblastoma                                    COG-N-453x                         Total RNA extraction       COG-N-453       IMDM, 20% FBS, 1% Penicillin/Streptomycin, 2 mM L-glutamine, 1:1,000 ITS Premix Supplement                    n/a
  COG-N-471nb cell line               Homo sapiens                         Neuroblastoma                                    COG-N-471x                         Total RNA extraction      COG-N-471nb        Neurobasal-A plus 50 ng/ml rhEGF, 50 ng/ml rhFGF, 2 mM L-glutamine, 1X B27, and 1X N2                  0.02% Versene
  COG-N-496 cell line                 Homo sapiens                         Neuroblastoma                                    COG-N-496x                         Total RNA extraction       COG-N-496       IMDM, 20% FBS, 1% Penicillin/Streptomycin, 2 mM L-glutamine, 1:1,000 ITS Premix Supplement               0.02% Versene
  COG-N-519 cell line                 Homo sapiens                         Neuroblastoma                                    COG-N-519x                         Total RNA extraction       COG-N-519       IMDM, 20% FBS, 1% Penicillin/Streptomycin, 2 mM L-glutamine, 1:1,000 ITS Premix Supplement               0.02% Versene
  COG-N-534 cell line                 Homo sapiens                         Neuroblastoma                                    COG-N-534m                         Total RNA extraction       COG-N-534       IMDM, 20% FBS, 1% Penicillin/Streptomycin, 2 mM L-glutamine, 1:1,000 ITS Premix Supplement               0.02% Versene
  COG-N-549 cell line                 Homo sapiens                         Neuroblastoma                                    COG-N-549x                         Total RNA extraction       COG-N-549       IMDM, 20% FBS, 1% Penicillin/Streptomycin, 2 mM L-glutamine, 1:1,000 ITS Premix Supplement               0.02% Versene
  COG-N-557nb cell line               Homo sapiens                         Neuroblastoma                                    COG-N-557x                         Total RNA extraction      COG-N-557nb        Neurobasal-A plus 50 ng/ml rhEGF, 50 ng/ml rhFGF, 2 mM L-glutamine, 1X B27, and 1X N2                  0.02% Versene
  COG-N-561 cell line                 Homo sapiens                         Neuroblastoma                                    COG-N-561x                         Total RNA extraction       COG-N-561       IMDM, 20% FBS, 1% Penicillin/Streptomycin, 2 mM L-glutamine, 1:1,000 ITS Premix Supplement               0.02% Versene
  COG-N-573 cell line                 Homo sapiens                         Neuroblastoma                                    COG-N-573x                         Total RNA extraction       COG-N-573       IMDM, 20% FBS, 1% Penicillin/Streptomycin, 2 mM L-glutamine, 1:1,000 ITS Premix Supplement               0.02% Versene
  Felix cell line                     Homo sapiens                         Neuroblastoma                                      FELIXx                           Total RNA extraction   Felix (COG-N-426)   IMDM, 20% FBS, 1% Penicillin/Streptomycin, 2 mM L-glutamine, 1:1,000 ITS Premix Supplement               0.02% Versene
  IMR-05 cell line                    Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction        IMR-05                     RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  IMR-32 cell line                    Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction        IMR-32                     RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  KELLY cell line                     Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction         KELLY                     RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  LA-N-5 cell line                    Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction        LA-N-5                     RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  LA-N-6 cell line                    Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction        LA-N-6                     RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  NB-1 cell line                      Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction         NB-1                      RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                                 n/a
  NB-16 cell line                     Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction         NB-16                     RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                          0.05% Trypsin/EDTA
  NB-1,643 cell line                  Homo sapiens                         Neuroblastoma                                     NB-1,643                          Total RNA extraction       NB-1,643                       IMDM, 20% FBS, 1% Penicillin/Streptomycin, 2 mM L-glutamine                                    n/a
  NB-1,691 cell line                  Homo sapiens                         Neuroblastoma                                     NB-1,691                          Total RNA extraction       NB-1,691                    RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                          0.05% Trypsin/EDTA
  NB-69 cell line                     Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction         NB-69                     RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  NB-EBc1 cell line                   Homo sapiens                         Neuroblastoma                                      NB-EBc1                          Total RNA extraction        NB-EBc1                    RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  NB-SD cell line                     Homo sapiens                         Neuroblastoma                                       NB-SD                           Total RNA extraction         NB-SD                     RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  NBL-S cell line                     Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction         NBL-S                     RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  NGP cell line                       Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction          NGP                      RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  NLFcell line                        Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction          NLF                      RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  NMB cell line                       Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction          NMB                      RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  RPE-1 cell line                     Homo sapiens                          Epithelial                                          NA                             Total RNA extraction         RPE-1                     RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                          0.05% Trypsin/EDTA
  SH-SY5Y cell line                   Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction        SH-SY5Y                    RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  SK-N-AS cell line                   Homo sapiens                         Neuroblastoma               SK-N-AS xenograft from cell line; not patient-derived   Total RNA extraction        SK-N-AS                    RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                          0.05% Trypsin/EDTA
  SK-N-BE(2) cell line                Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction      SK-N-BE(2)                   RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  SK-N-BE(2)-C cell line              Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction     SK-N-BE(2)-C                  RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  SK-N-DZ cell line                   Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction        SK-N-DZ                    RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  SK-N-FI cell line                   Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction        SK-N-FI                    RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  SK-N-SH cell line                   Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction        SK-N-SH                    RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                          0.05% Trypsin/EDTA
  SMS-KAN cell line                   Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction        SMS-KAN                    RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  SMS-SAN cell line                   Homo sapiens                         Neuroblastoma                                        NA                             Total RNA extraction        SMS-SAN                    RPMI 1,640, 10% FBS, 1% Penicillin/Streptomycin, 2 mM L-Glutamine                            0.02% Versene
  Human Fetal Brain                   Homo sapiens                             Brain                                            NA                                      NA                  Brain                                                     NA                                                                 NA

###### Associated metadata for the RNA-Seq assay

  **Cell Line**         **Data ID**     **Assay Name**   **Raw Data File Name 1**   **Raw Data File Name 2**   **Data Repository**                               **Data Accession Number**                                            **Derived Data File Name**               **Data Repository**   **Data Accession Number**
  ------------------- ---------------- ---------------- -------------------------- -------------------------- --------------------- ------------------------------------------------------------------------------------ ---------------------------------------------------- --------------------- ---------------------------
  CHP-134                  CHP134          RNA-Seq             CHP134.R1.fq               CHP134.R2.fq                 GEO           [[GSM2371222](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371222)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  CHP-212                  CHP212          RNA-Seq             CHP212.R1.fq               CHP212.R2.fq                 GEO           [[GSM2371223](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371223)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  COG-N-415               COGN415          RNA-Seq            COGN415.R1.fq              COGN415.R2.fq                 GEO           [[GSM2371224](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371224)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  COG-N-440               COGN440          RNA-Seq            COGN440.R1.fq              COGN440.R2.fq                 GEO           [[GSM2371225](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371225)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  COG-N-453               COGN453          RNA-Seq            COGN453.R1.fq              COGN453.R2.fq                 GEO           [[GSM2371226](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371226)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  COG-N-471nb             COGN471          RNA-Seq            COGN471.R1.fq              COGN471.R2.fq                 GEO           [[GSM2371227](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371227)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  COG-N-496               COGN496          RNA-Seq            COGN496.R1.fq              COGN496.R2.fq                 GEO           [[GSM2371228](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371228)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  COG-N-519               COGN519          RNA-Seq            COGN519.R1.fq              COGN519.R2.fq                 GEO           [[GSM2371229](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371229)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  COG-N-534               COGN534          RNA-Seq            COGN534.R1.fq              COGN534.R2.fq                 GEO           [[GSM2371230](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371230)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  COG-N-549               COGN549          RNA-Seq            COGN549.R1.fq              COGN549.R2.fq                 GEO           [[GSM2371231](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371231)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  COG-N-557nb             COGN557          RNA-Seq            COGN557.R1.fq              COGN557.R2.fq                 GEO           [[GSM2371232](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371232)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  COG-N-561               COGN561          RNA-Seq            COGN561.R1.fq              COGN561.R2.fq                 GEO           [[GSM2371233](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371233)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  COG-N-573               COGN573          RNA-Seq            COGN573.R1.fq              COGN573.R2.fq                 GEO           [[GSM2371234](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371234)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  Felix (COG-N-426)        FELIX           RNA-Seq             FELIX.R1.fq                FELIX.R2.fq                  GEO           [[GSM2371235](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371235)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  IMR-05                   IMR05           RNA-Seq             IMR05.R1.fq                IMR05.R2.fq                  GEO           [[GSM2371236](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371236)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  IMR-32                   IMR32           RNA-Seq             IMR32.R1.fq                IMR32.R2.fq                  GEO           [[GSM2371237](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371237)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  KELLY                    KELLY           RNA-Seq             KELLY.R1.fq                KELLY.R2.fq                  GEO           [[GSM2371238](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371238)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  LA-N-5                    LAN5           RNA-Seq              LAN5.R1.fq                 LAN5.R2.fq                  GEO           [[GSM2371239](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371239)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  LA-N-6                    LAN6           RNA-Seq              LAN6.R1.fq                 LAN6.R2.fq                  GEO           [[GSM2371240](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371240)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  NB-1                      NB1            RNA-Seq              NB1.R1.fq                  NB1.R2.fq                   GEO           [[GSM2371241](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371241)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  NB-16                     NB16           RNA-Seq              NB16.R1.fq                 NB16.R2.fq                  GEO           [[GSM2371242](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371242)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  NB-1643                  NB1643          RNA-Seq             NB1643.R1.fq               NB1643.R2.fq                 GEO           [[GSM2371243](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371243)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  NB-1691                  NB1691          RNA-Seq             NB1691.R1.fq               NB1691.R2.fq                 GEO           [[GSM2371244](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371244)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  NB-69                     NB69           RNA-Seq              NB69.R1.fq                 NB69.R2.fq                  GEO           [[GSM2371245](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371245)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  NB-EBc1                  NBEBC1          RNA-Seq             NBEBC1.R1.fq               NBEBC1.R2.fq                 GEO           [[GSM2371246](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371246)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  NB-SD                     NBSD           RNA-Seq              NBSD.R1.fq                 NBSD.R2.fq                  GEO           [[GSM2371247](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371247)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  NBL-S                     NBLS           RNA-Seq              NBLS.R1.fq                 NBLS.R2.fq                  GEO           [[GSM2371248](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371248)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  NGP                       NGP            RNA-Seq              NGP.R1.fq                  NGP.R2.fq                   GEO           [[GSM2371249](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371249)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  NLF                       NLF            RNA-Seq              NLF.R1.fq                  NLF.R2.fq                   GEO           [[GSM2371250](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371250)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  NMB                       NMB            RNA-Seq              NMB.R1.fq                  NMB.R2.fq                   GEO           [[GSM2371251](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371251)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  RPE-1                     RPE1           RNA-Seq              RPE1.R1.fq                 RPE1.R2.fq                  GEO           [[GSM2371252](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371252)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  SH-SY5Y                  SHSY5Y          RNA-Seq             SHSY5Y.R1.fq               SHSY5Y.R2.fq                 GEO           [[GSM2371253](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371253)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  SK-N-AS                  SKNAS           RNA-Seq             SKNAS.R1.fq                SKNAS.R2.fq                  GEO           [[GSM2371254](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371254)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  SK-N-BE(2)               SKNBE2          RNA-Seq             SKNBE2.R1.fq               SKNBE2.R2.fq                 GEO           [[GSM2371255](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371255)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  SK-N-BE(2)-C            SKNBE2C          RNA-Seq            SKNBE2C.R1.fq              SKNBE2C.R2.fq                 GEO           [[GSM2371256](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371256)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  SK-N-DZ                  SKNDZ           RNA-Seq             SKNDZ.R1.fq                SKNDZ.R2.fq                  GEO           [[GSM2371257](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371257)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  SK-N-FI                  SKNFI           RNA-Seq             SKNFI.R1.fq                SKNFI.R2.fq                  GEO           [[GSM2371258](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371258)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  SK-N-SH                  SKNSH           RNA-Seq             SKNSH.R1.fq                SKNSH.R2.fq                  GEO           [[GSM2371259](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371259)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  SMS-KAN                  SMSKAN          RNA-Seq             SMSKAN.R1.fq               SMSKAN.R2.fq                 GEO           [[GSM2371260](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371260)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  SMS-SAN                  SMSSAN          RNA-Seq             SMSSAN.R1.fq               SMSSAN.R2.fq                 GEO           [[GSM2371261](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371261)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413
  Human Fetal Brain    HU-FETAL-BRAIN      RNA-Seq         HU-FETAL-BRAIN.R1.fq       HU-FETAL-BRAIN.R2.fq             GEO           [[GSM2371262](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM2371262)]{.ul}   GSE89413_2016-10-30-NBL-cell-line-STAR-fpkm.txt.gz           GEO                   GSE89413

###### Genetic lesion profiles for the neuroblastoma cell lines

  **Cell Line**        **MYCN status**                      **1p36 del**                                  **3p26 del**                      **11q23 del**            **17q21-qter unbal gain**   **ALK mutation**   **p53 mutation**
  ------------------- ----------------- ----------------------------------------------------- ------------------------------------ -------------------------------- --------------------------- ------------------ ------------------
  CHP-134                 Amplified      LOH p32.3-pter; Gain p34.3-p36.22; Loss p36.22-pter             Gain/AI p26.3                           None                      Gain q12-qter                WT                 WT
  CHP-212                 Amplified                        Loss p13.2-pter                               Gain/AI p26.3                        cnLOH 23.3                   Gain q12-qter                WT                 WT
  COG-N-415               Amplified                            Unknown                                      Unknown                            Unknown                        Unknown                 F1174L               WT
  COG-N-440               Amplified                            Unknown                                      Unknown                            Unknown                        Unknown                   WT                 WT
  COG-N-453               Amplified                            Unknown                                      Unknown                            Unknown                        Unknown                 F1174L               WT
  COG-N-471nb             Amplified                            Unknown                                      Unknown                            Unknown                        Unknown                   WT                 WT
  COG-N-496               Amplified                            Unknown                                      Unknown                            Unknown                        Unknown                Unknown            Unknown
  COG-N-519               Amplified                            Unknown                                      Unknown                            Unknown                        Unknown                Unknown            Unknown
  COG-N-534             Non-amplified                          Unknown                                      Unknown                            Unknown                        Unknown                Unknown            Unknown
  COG-N-549             Non-amplified                          Unknown                                      Unknown                            Unknown                        Unknown                Unknown            Unknown
  COG-N-557nb             Amplified                            Unknown                                      Unknown                            Unknown                        Unknown                Unknown            Unknown
  COG-N-561               Amplified                            Unknown                                      Unknown                            Unknown                        Unknown                Unknown            Unknown
  COG-N-573               Amplified                            Unknown                                      Unknown                            Unknown                        Unknown                Unknown            Unknown
  FELIX (COG-N-426)     Non-amplified                          Unknown                                      Unknown                            Unknown                        Unknown                 F1245C               WT
  IMR-05                  Amplified                      Gain+LOH p32.3-pter                           Gain/AI p24.3-26.3                  Loss q22.1-qter                Gain q21.2-qter               WT                 WT
  IMR-32                  Amplified                        Loss p32.3-pter                                 Loss p12.3                        cnLOH q23.1                  Gain q21.2-qter               WT                 WT
  KELLY                   Amplified           LOH p21.3-pter; Loss p36.32; Gain p36.33                     Loss p26.2                      Loss q23.3-qter                Gain q21.2-qter             F1174L             P177T
  LA-N-5                  Amplified                         Loss p33-pter                                     None                               None                     Gain q21.2-qter             R1275Q               WT
  LA-N-6                Non-amplified              p36.12-pter; cnLOH p35.3-p36.11                      Loss p14.3-pter                    Loss q13.4-qter                 Gain q12-qter                WT                 WT
  NB-1                    Amplified                        Loss p32.2-pter                              Gain p24.1-pter                      cnLOH q23.1                   Gain q22-qter          WT; amplified            WT
  NB-16                 Non-amplified                           None                                          None                               None                      Unresolvable                 WT            R248W, R175H
  NB-1,643                Amplified                        Loss p34.2-pter                                    None                         Loss q23.1-qter               Gain q21.31-qter             R1275Q               WT
  NB-1,691                Amplified                             None                                       Loss p26.1               LOH q11-qter; Loss q22.1-q24.3             None?                    WT                 WT
  NB-69                 Non-amplified                      Loss p13.3-pter                                    None                        cnLOH q23.1, q23.3               Gain q12-qter                WT                 WT
  NB-EBc1               Non-amplified                      Loss p35.2-pter                              Gain p26.1-pter                     Loss q21-24.2                Gain q21.31-qter               WT                 WT
  NB-SD                   Amplified                        Loss p21.3-pter                               Loss p13-pter                     cnLOH q23.2-23.3                Gain q12-qter              F1174L             C176F
  NBL-S                 Non-amplified                           None                                          None                         Loss q14.1-qter                     None                     WT                 WT
  NGP                     Amplified                       cnLOH p32.3-pter                              Gain p25.3-pter                    Loss q22.1-qter                Gain q21.1-qter               WT            A159D, C141W
  NLF                     Amplified                        Loss p32.2-pter                     Loss/AI p26.1; AI p26.2; Gain 26.3         Loss/AI q23.3-qter              Gain q21.2-qter               WT               V203M
  NMB                     Amplified                       cnLOH p34.2-pter                                    None                          Loss q21-qter               LOH/Gain q11.2-qter             WT               G245S
  RPE-1                 Non-amplified                          Unknown                                      Unknown                            Unknown                        Unknown                   WT                 WT
  SH-SY5Y               Non-amplified                           None                                          None                         Loss q22.1-q24.2              Gain q21.31-qter             F1174L               WT
  SK-N-AS               Non-amplified                     Loss p36.22-36.32                             Loss p14.2-pter                       q13.4-qter                 Gain q21.31-qter               WT               H168R
  SK-N-BE(2)              Amplified                       cnLOH p21.3-pter                              Loss p14.2-pter                   Gain/AI q13.1-qter               Gain q12-qter                WT               C135F
  SK-N-BE(2)-C            Amplified                       cnLOH p21.3-pter                              Loss p14.2-pter             LOH q11-qter; Gain q13.4-qter          Gain q12-qter                WT               C135F
  SK-N-DZ                 Amplified                             None                                   Gain/AI p26.1-pter                   Loss q21-qter                 Gain q21.2-qter               WT               R110L
  SK-N-FI               Non-amplified                           None                                          None                               None                    Gain q21.31-qter               WT               M246R
  SK-N-SH               Non-amplified                           None                                          None                               None                    Gain q21.31-qter             F1174L               WT
  SMS-KAN                 Amplified                        Loss p13.3-pter                                    None                         Loss q14.2-q23.3               Gain q11.1-qter               WT                 WT
  SMS-SAN                 Amplified                        Loss p32.3-pter                                    None                             Loss q25                   Gain q21.2-qter             F1174L               WT

[^1]: J.H. and J.M.M. conceived the experiment. J.H. designed the experiment, collected samples, performed QC and data analysis, and wrote the manuscript. J.H. and L.S.H. cultured the cell lines. M.A.D. extracted RNA samples and prepared them for sequencing. RNA performed library preps and sequenced the samples under the guidance of P.F. From separate cell pellets, J.H., M.A.D., and M.H.D. extracted DNA for STR typing. M.J.S., H.L.D., and C.P.R. established and validated COG cell lines. All authors read and approved of the final manuscript.
